CAMBRIDGE, Mass. September 17, 2020 – (BUSINESSWIRE) –

Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced its Scientific Advisory Board (SAB). The SAB will help guide the advancement of the company’s pipeline of small molecule solutions for the treatment of Obstructive Sleep Apnea, or OSA.

“OSA represents a significant health problem for more than 25 million Americans, with some estimates significantly higher, and hundreds of millions more around the globe,” said Larry Miller, M.D. chief executive officer of Apnimed. “We are honored to have a group of highly esteemed leaders join our Scientific Advisory Board as we advance multiple pharmaceutical programs to address the significant unmet needs of patients suffering from and at risk of serious complications due to OSA.”

Members of the Apnimed Scientific Advisory Board:

  • John Cronin, M.D., Chief Medical Officer, Sleep and Respiratory Care, Philips Healthcare
  • Danny Eckert, Ph.D., Director, Adelaide Institute for Sleep Health, Deputy Director Flinders Health and Medical Research Institute and Matthew Flinders Professor, College of Medicine and Public Health at Flinders University
  • Diane Lim, M.D., Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran’s Administration Medical Center
  • Reena Mehra, M.D., M.S., Professor of Medicine, Cleveland Clinic Lerner College of Medicine and Director, Sleep Disorders Research, Neurologic Institute
  • Carlos M. Nunez, M.D., Chief Medical Officer at ResMed
  • Naresh Punjabi, M.D. Ph.D., Chief, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine at University of Miami Health System, Jackson Memorial Hospital
  • Susan Redline, M.D., M.P.H., Director, Sleep Medicine Epidemiology, Physician, Brigham and Women’s Hospital, and Professor of Medicine, Harvard Medical School
  • Alan Schwartz, M.D., Professor of Medicine, ret., Johns Hopkins University and Adjunct Professor, Perelman School of Medicine, University of Pennsylvania
  • Andrew Wellman, M.D, Ph.D., Director, Sleep Disordered Breathing Lab at Brigham and Women’s Hospital and Associate Professor, Harvard Medical School

About Obstructive Sleep Apnea

Obstructive Sleep Apnea (OSA) is one of the most common and serious sleep disorders and is estimated to affect more than 25 million Americans, though underdiagnosis continues to be a serious problem. OSA is characterized by partial or complete upper airway closure that occurs during sleep, which often leads to poor sleep, and in the long-term, hypertension, diabetes, cardiovascular disease, strokes, and early mortality. The vast majority of diagnosed patients are prescribed positive air pressure therapy devices such as continuous positive airway pressure, or CPAP, but fewer than half are compliant long-term, leaving a significant population untreated and at risk.

About Apnimed

Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea will benefit from treatment with a safe and effective oral medication. Apnimed’s lead development program targets nighttime neurotransmitter levels in the central nervous system to activate upper airway muscles and maintain an open airway during sleep. The drug is delivered as a convenient once-a-day dose before bed. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.

Learn more at

Media Contact:
Courtney Heath

Investor Contact:
Elizabeth Woo
Kendall IR